Northwest Biotherapeutics

Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors

Retrieved on: 
Thursday, March 21, 2024
Research, Mechanical, AMIBIOS, Master, Biotechnology, AMI, Georgia Tech, Senior ice hockey, National Hockey League, University, Software, IBM, Audit committee, Bachelor, American Megatrends, Compensation, Northwest Biotherapeutics, Heart, Operation, BIOS, OTCQB, Nursing

Mr. Sarma will serve as the Chairman of the Audit Committee and member of the Compensation and Conflicts Committees.

Key Points: 
  • Mr. Sarma will serve as the Chairman of the Audit Committee and member of the Compensation and Conflicts Committees.
  • In the joining the Board, he brings decades of experience as a business executive and as a venture capital investor.
  • Mr. Sarma's interests in AMI were acquired, and thereafter he became a venture capital investor in the private equity markets.
  • Mr. Sarma commented, "I am honored to be asked to join the Board of NWBio at this exciting and pivotal time in the Company's history.

Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma

Retrieved on: 
Thursday, December 21, 2023
Neoplasm, Survival, B cell, Northwest Biotherapeutics, Biotechnology, Research, Marketing, TCR, MAA, Medication, Sponsor, Recurrence, MHRA, GMP, Glioblastoma, ChromeOS, OTCQB, Cancer, Central nervous system, Patient, Peptide, Trial master file, PNAS, Medical imaging

BETHESDA, Md., Dec. 21, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that a Marketing Authorization Application (MAA) was submitted yesterday to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for DCVax®-L for glioblastoma brain cancer.

Key Points: 
  • The MAA seeks approval for commercialization of DCVax-L for both newly diagnosed and recurrent glioblastoma (GBM).
  • We believe DCVax-L can offer a much needed new treatment option for GBM patients, both alone and in combination with other treatment agents.
  • We look forward to bringing the treatment to as many patients as possible, including in community settings where most patients are treated."
  • The Company looks forward to resuming its clinical development of DCVax-Direct for a wide range of inoperable solid tumors.

Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma

Retrieved on: 
Thursday, December 21, 2023
Neoplasm, Survival, B cell, Northwest Biotherapeutics, Biotechnology, Research, Marketing, TCR, MAA, Medication, Sponsor, Recurrence, MHRA, GMP, Glioblastoma, ChromeOS, OTCQB, Cancer, Central nervous system, Patient, Peptide, Trial master file, PNAS, Medical imaging

BETHESDA, Md., Dec. 21, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that a Marketing Authorization Application (MAA) was submitted yesterday to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for DCVax®-L for glioblastoma brain cancer.

Key Points: 
  • The MAA seeks approval for commercialization of DCVax-L for both newly diagnosed and recurrent glioblastoma (GBM).
  • We believe DCVax-L can offer a much needed new treatment option for GBM patients, both alone and in combination with other treatment agents.
  • We look forward to bringing the treatment to as many patients as possible, including in community settings where most patients are treated."
  • The Company looks forward to resuming its clinical development of DCVax-Direct for a wide range of inoperable solid tumors.

Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit

Retrieved on: 
Wednesday, December 13, 2023
Biotechnology, Pharmaceutical, Oncology, General Health, Health, Infectious Diseases, Hospitals, Clinical Trials, NSC, B cell, M.D, Research, Safety, NYSE, Immune system, City, Northwestern University, HGG, Clinical trial, IND, SNV, Brain tumor, Northwest Biotherapeutics, Supernova, Patient, Tumor microenvironment, Medicine, Neoplasm, University, Virus, NNV, Pharmaceutical industry, Vaccine, Boston

“Our cell-based virotherapeutics are designed to target tumors directly and to help the immune system recognize and attack distant tumor sites,” said Boris R. Minev.

Key Points: 
  • “Our cell-based virotherapeutics are designed to target tumors directly and to help the immune system recognize and attack distant tumor sites,” said Boris R. Minev.
  • Updates to be presented at the upcoming 8th Oncolytic Virotherapy Summit include:
    Progress in Recurrent High Grade Glioma (HGG) Trial.
  • Calidi plans to commence a Phase 1b/2 clinical trial for NeuroNova (NNV1) in collaboration with Northwestern University during the first half of 2024.
  • The company’s research is focused on engineered oncolytic vaccinia virus to increase the tumor specificity and oncolytic potency with improved systemic anti-tumor immunity.

Calidi Biotherapeutics Announces Appointment of Pharmaceutical Industry Veteran David LaPré to its Board of Directors

Retrieved on: 
Tuesday, December 12, 2023
Research, Public Relations, Investor Relations, Communications, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, NYSE, Northwest Biotherapeutics, Worcester Polytechnic Institute, Management, Engineering, New York University

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the appointment of David LaPré to the company’s Board of Directors effective January 1, 2024.

Key Points: 
  • Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the appointment of David LaPré to the company’s Board of Directors effective January 1, 2024.
  • “David LaPré brings a wealth of pharmaceutical industry experience, expertise in solving problems unique to this industry, and a solid understanding of the factors that drive shareholder value.
  • His past experiences will help Calidi move forward as a company, advancing our portfolio of cancer immunotherapies into later stage clinical trials,” said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics.
  • “I look forward to guiding Calidi’s team and helping them improve operational excellence as they mature their organization.”

Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting

Retrieved on: 
Monday, December 11, 2023
Biotechnology, Pharmaceutical, Health, ATRA, Epstein–Barr virus, TCR, Gene editing, Phenotype, Lymphoid leukemia, ASH, IND, Risk, Northwest Biotherapeutics, B-cell lymphoma, HCT, Head, Patient, CD19, Autoimmune disease, Acute lymphoblastic leukemia, HLA, Cancer, Survival, CD20, EBV, Society, Cell, Vaccine, Atara

Findings support ATA3431 advancement into clinical testing, initially focused on the treatment of B-cell malignancies.

Key Points: 
  • Findings support ATA3431 advancement into clinical testing, initially focused on the treatment of B-cell malignancies.
  • The data will be presented in a poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting taking place December 9-12, 2023, in San Diego.
  • ATA3431 also incorporates the clinically validated 1XX costimulatory domain that enhances stemness and modulates exhaustion to extend functional persistence.
  • Compared to an autologous CD20/CD19 CAR-T benchmark, the ATA3431 preclinical data demonstrate potent antitumor activity, long-term persistence, and superior tumor growth inhibition.

Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023

Retrieved on: 
Wednesday, November 29, 2023
Oncology, Health, Stem Cells, Clinical Trials, Research, Science, Biotechnology, CNS, ATRA, Epstein–Barr virus, Safety, Partial-response maximum-likelihood, PST, Disease, Northwest Biotherapeutics, ESMO, HCT, Patient, CET, ORR, SOT, Cancer, Symantec Endpoint Protection, PTLD, Neurotoxicity, Congress, Central nervous system, EBV, TTR, OS, PR, Vaccine, Pharmaceutical industry

These results will be presented as an oral session at the European Society for Medical Oncology Immuno-Oncology (ESMO I‑O) Annual Congress taking place December 6-8, 2023, in Geneva, Switzerland.

Key Points: 
  • These results will be presented as an oral session at the European Society for Medical Oncology Immuno-Oncology (ESMO I‑O) Annual Congress taking place December 6-8, 2023, in Geneva, Switzerland.
  • “We’re pleased to share new multicenter data, including the first results from our ongoing multicohort EBVision trial and first clinical trial report of treatment with tab-cel in the first line setting.
  • The estimated one-year overall survival (OS) rate was 70.6% (95% CI: 43.0, 86.6) for all patients.
  • Date & Time: December 7, 2023, at 2:15 - 3:45 p.m. CET / 5:15 - 6:45 a.m. PST

Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference

Retrieved on: 
Wednesday, November 22, 2023
Oncology, Health, Genetics, Other Health, General Health, Pharmaceutical, Biotechnology, ATRA, Webcast, Epstein–Barr virus, EST, Northwest Biotherapeutics, EBV, Cancer, Patient, Conference, Pharmaceutical industry, Broadcasting

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 10:50 a.m. EST.

Key Points: 
  • Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 10:50 a.m. EST.
  • A live webcast of the presentation will be available by visiting the Investors and Media section of atarabio.com .
  • An archived replay of the webcast will be available on the Company's website for 30 days following the live presentation.

Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform and Updates Anticipated Clinical Milestones

Retrieved on: 
Monday, November 20, 2023
Health Technology, Health, Oncology, NYSE, Immune system, Clinical trial, Northwest Biotherapeutics, Supernova, Patient, Patent, Cell, Vaccine

In addition, the company also provided an update on the timing of its anticipated clinical milestones.

Key Points: 
  • In addition, the company also provided an update on the timing of its anticipated clinical milestones.
  • The United States Patent and Trademark Office (USPTO) has issued U.S. Patent No.
  • “This latest patent granted to Calidi covering meaningful features of our SuperNova platform represents an important milestone as we prepare to advance CLD-201 into the clinic,” said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics.
  • In addition, Calidi also provided updates on the timing for certain anticipated clinical milestones for its NeuroNova and SuperNova platforms.

Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Results

Retrieved on: 
Tuesday, November 14, 2023
Oncology, Health, Stem Cells, Clinical Trials, Pharmaceutical, Biotechnology, Research, Safety, NYSE, Annual general meeting, Therapy, Northwest Biotherapeutics, Supernova, Patient, Immunotherapy, Neoplasm, NYSE American, Partnership, SITC, Growth, Society, Poster, Pharmaceutical industry, Cryptocurrency

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, reports its financial results for the third quarter 2023 and reviews recent business highlights.

Key Points: 
  • Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, reports its financial results for the third quarter 2023 and reviews recent business highlights.
  • The poster also detailed the clinical readiness of the product and plans to launch a Phase 1 study in 2024.
  • The company also announced the appointment of Alan Stewart, previously a Calidi advisor, to the Board of Directors.
  • In conjunction with the transaction closing, Calidi entered into a forward purchase agreement with a consortium of funds for up to $10 million.